Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
Alzheimer's Disease & Dementia, COVID-19

Gabriel A de Erausquin, AAIC 2021: The Alzheimer’s Association-led Global SARS-CoV-2 Consortium

Copy Link
Published Online: Sep 2nd 2021

touchNEUROLOGY joins Gabriel de Erausquin (UT Health San Antonio, TX, USA) at AAIC 2021 to discuss the Alzheimer’s Association-led Global SARS-CoV-2 Consortium and the links between long-term cognitive dysfunction, acceleration of Alzheimer’s symptoms and COVID-19.

Questions

  1. Could you tell us a little about the Alzheimer’s Association-led global SARS-CoV-2 consortium? (00:30-02:07)
  2. What were the aims and design of the cohort study you presented at AAIC? (02:07-04:01)
  3. What symptoms of cognitive impairment were found, and how did these correlate with olfactory symptoms and COVID-19 severity? (04:01-07:05)
  4. What unanswered questions remain regarding this association? (07:05-10:12)

Disclosures: Prof de Erausquin has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2021 AAIC Annual Meeting.

Share this Video
Related Videos In COVID-19
COVID-19, Parkinson's Disease
Developed by Touch
Suman Kushwaha, MDS 2022: COVID-19 vaccine induced parkinsonism and cognitive dysfunction
Watch Time: 6 mins

Two cases of COVID-19 vaccination associated neurological symptoms were presented, with patients displaying parkinsonism and cognitive dysfunction. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behaviour and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms and investigations leading to the case report conclusions.  The abstract entitled […]

COVID-19, Parkinson's Disease
Developed by Touch
Suman Kushwaha, MDS 2022: Neurological symptoms and COVID-19 vaccination
Watch Time: 2 mins

Neurological complications, such as peripheral neuropathy, have been associated with COVID-19 vaccination. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behavior and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms that have been observed.  The abstract entitled ‘Covid vaccine induced parkinsonism and cognitive dysfunction’ was presented […]

COVID-19, Headache Disorders
Developed by Touch
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Watch Time: 05:55 mins

Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]

Trending In COVID-19:

Suman Kushwaha, MDS 2022: COVID-19 vaccine induced parkinsonism and cognitive dysfunction
COVID-19, Parkinson's Disease
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32 social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72